Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hung Hung

Showing results (541-550 of 563) with videos related to

Pageof 57
Sort By:
Journal of Gastroenterology and Hepatology|May 8, 2021
Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort)Wei-Fan Hsu, Pei-Chein Tsai, Chi-Yi Chen, et al.
Journal of Hepatology|October 8, 2022
Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in TaiwanPei-Chien Tsai, Hsing-Tao Kuo, Chao-Hung Hung, et al.
Journal of Gastroenterology and Hepatology|February 24, 2021
Long-term risk of end-stage renal diseases with maintenance dialysis among chronic hepatitis C patients after antiviral therapy in TaiwanMeng-Hsuan Hsieh, Ming-Jong Bair, Pei-Chien Tsai, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|March 1, 2025
Posttreatment FIB-4 score change predicts hepatocellular carcinoma in chronic hepatitis C patients: Findings from the Taiwan hepatitis C registry programHung-Wei Wang, Yu-Syuan Zeng, Chung-Feng Huang, et al.
Open Forum Infectious Diseases|December 30, 2020
Successful Antiviral Therapy Reduces Risk of Schizophrenia Among Chronic Hepatitis C Patients: A Nationwide Real-World Taiwanese Cohort (T-COACH)Pei-Chien Tsai, Chi-Yi Chen, Hsing-Tao Kuo, et al.
The Kaohsiung Journal of Medical Sciences|May 24, 2025
Impact of Hepatitis C Virus Clearance on Cardiovascular Risk: A Real-World Experience From the Nationwide Taiwan Hepatitis C Virus RegistryPing-Jen Hu, Pei-Chien Tsai, Chi-Yi Chen, et al.
Clinical and Molecular Hepatology|April 19, 2024
Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapyPei-Chien Tsai, Chung-Feng Huang, Ming-Lun Yeh, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|June 10, 2025
Long-term risk of depression and the impact of risk factors among chronic hepatitis C patients after successful antiviral therapy: A nationwide real-world Taiwanese cohort (T-COACH)Ping-Jen Hu, Ming-Lung Yu, Ming-Yao Chen, et al.
Scientific Reports|December 7, 2021
Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in TaiwanChung-Feng Huang, Hsing-Tao Kuo, Te-Sheng Chang, et al.
The Kaohsiung Journal of Medical Sciences|June 20, 2025
Effects of Sofosbuvir/Velpatasvir Therapy on Extrahepatic Manifestations in Patients With Type 2 Diabetes and Chronic Hepatitis C: Insights From a Nationwide Hepatitis C Virus Registry in TaiwanSzu-Jen Wang, Te-Sheng Chang, Ching-Chu Lo, et al.
Pageof 57

Showing results (541-550 of 563) with videos related to

Sort By:
Pageof 57
Journal of Gastroenterology and Hepatology|May 8, 2021
Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort)Wei-Fan Hsu, Pei-Chein Tsai, Chi-Yi Chen, et al.
Journal of Hepatology|October 8, 2022
Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in TaiwanPei-Chien Tsai, Hsing-Tao Kuo, Chao-Hung Hung, et al.
Journal of Gastroenterology and Hepatology|February 24, 2021
Long-term risk of end-stage renal diseases with maintenance dialysis among chronic hepatitis C patients after antiviral therapy in TaiwanMeng-Hsuan Hsieh, Ming-Jong Bair, Pei-Chien Tsai, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|March 1, 2025
Posttreatment FIB-4 score change predicts hepatocellular carcinoma in chronic hepatitis C patients: Findings from the Taiwan hepatitis C registry programHung-Wei Wang, Yu-Syuan Zeng, Chung-Feng Huang, et al.
Open Forum Infectious Diseases|December 30, 2020
Successful Antiviral Therapy Reduces Risk of Schizophrenia Among Chronic Hepatitis C Patients: A Nationwide Real-World Taiwanese Cohort (T-COACH)Pei-Chien Tsai, Chi-Yi Chen, Hsing-Tao Kuo, et al.
The Kaohsiung Journal of Medical Sciences|May 24, 2025
Impact of Hepatitis C Virus Clearance on Cardiovascular Risk: A Real-World Experience From the Nationwide Taiwan Hepatitis C Virus RegistryPing-Jen Hu, Pei-Chien Tsai, Chi-Yi Chen, et al.
Clinical and Molecular Hepatology|April 19, 2024
Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapyPei-Chien Tsai, Chung-Feng Huang, Ming-Lun Yeh, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|June 10, 2025
Long-term risk of depression and the impact of risk factors among chronic hepatitis C patients after successful antiviral therapy: A nationwide real-world Taiwanese cohort (T-COACH)Ping-Jen Hu, Ming-Lung Yu, Ming-Yao Chen, et al.
Scientific Reports|December 7, 2021
Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in TaiwanChung-Feng Huang, Hsing-Tao Kuo, Te-Sheng Chang, et al.
The Kaohsiung Journal of Medical Sciences|June 20, 2025
Effects of Sofosbuvir/Velpatasvir Therapy on Extrahepatic Manifestations in Patients With Type 2 Diabetes and Chronic Hepatitis C: Insights From a Nationwide Hepatitis C Virus Registry in TaiwanSzu-Jen Wang, Te-Sheng Chang, Ching-Chu Lo, et al.
Pageof 57